Manager TitleAgeSince
Chief Executive Officer 60 09/05/2022
Chief Operating Officer 51 05/09/2023
Chief Tech/Sci/R&D Officer 51 01/08/2022
Change 5-day change 1-year change 3-year change Capi.($)
-35.06%-47.37% - - 418K
+3.19%+11.31%+67.86%+150.58% 1,263B
-0.73%+3.56%+44.51%+85.81% 658B
+1.41%+3.24%+29.22%+107.83% 521B
+0.42%+3.20%+54.15%+67.18% 391B
+2.18%+2.93%+73.30%+45.62% 369B
+1.12%+4.52%+35.30%+58.08% 307B
+6.96%+8.86%+11.27%+36.62% 290B
+1.15%+6.09%+59.59%+77.06% 252B
+3.06%+9.38%+44.11%+119.47% 212B
Average -1.95%+5.90%+46.59%+83.14% 473.55B
Weighted average by Cap. +1.19%+6.60%+50.88%+98.31%
Logo Ziccum AB
Ziccum AB is a Sweden-based pharmaceutical company that is mainly engaged in developing vaccines. Ziccum develops new thermostable versions of vaccines and biologics for licensing to vaccine suppliers, developers, manufacturers and CDMOs in the global pharmaceutical industry. Ziccum's patented drying technology, LaminarPace, is unique. It can dry-formulate temperature-sensitive vaccine materials at room temperature with high yield and low waste. These robust, thermostable dry powders can be stored and transported worldwide without the need for a cold chain or freezing. The company conducts its business by entering into strategic collaborations with major pharmaceutical companies and offering licenses to the Company's patented technology.
Employees
10
  1. Stock Market
  2. Stocks
  3. ZICC Stock